$XAIR Cashflow Statement | Understand Stock

$XAIR

$2.21 +$0.07 (3.27%) Close

$XAIR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2026 12 months to Mar 31, 2026	FY2025 12 months to Mar 31, 2025	FY2024 12 months to Mar 31, 2024	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Depreciation
Amortization of debt discount and accretion of debt issuance costs
Amortization of licensed right to use technology
Amortization of operating lease assets
Foreign currency adjustment
Amortization of debt issuance cost and deferred financing fees
Change in fair value of warrant liability
Change in fair value of derivative liability
Unrealized loss on marketable securities
Disposal of clinical and medical equipment
Provision for inventory losses
Provision for bad debt
Foreign currency adjustments
Loss on extinguishment of debt
Impairment of fixed assets
Loss on disposal of fixed assets
Paid in kind interest
Changes in:
Grant receivable
Inventory
Accounts receivable
Other current assets and prepaid expenses
Accounts payable
Accrued expenses
Operating lease liabilities
Long-term accrued liabilities

Net cash used in operating activities
Cash flows from investing activities:
Security deposits made on rental properties
Purchase of marketable securities
Proceeds from sale of marketable securities
Security deposits made on operating leases
Purchase of property and equipment
Net cash (used in)/provided by investing activities

Cash flows from financing activities:
Proceeds from issuance of common stock through at the market offerings, net
Proceeds from the sale of common stock of NeuroNos
Proceeds from issuance of common stock
Proceeds from issuance of common stock in connection with a purchase agreement
Proceeds from the net recovery of short-swing profits from related parties
Proceeds from loan
Proceeds from issuance of common stock through exercise of options
Proceeds from issuance of common stock through exercise of warrants
Proceeds from issuance of common stock warrants
Proceeds from long term loan
Debt issuance costs
Payment of loan
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Increase/(decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental disclosure of non-cash investing and financing activities:
Debt discount
End of term loan liability
Warrant liability
Derivative liability
Short term finance liability
Right-of-use lease assets
Accelerated amortization of debt discount costs on retirement of debt
Increase in Licensed Right to Use Technology from NitricGen agreement
NitricGen accrued liability due to FDA approval
Fixed assets recorded in accounts payable and accrued expenses
Right-of-use assets acquired under operating leases
Debt principal balance converted to equity
Interest paid
Income taxes paid

Comments